Skip to main content
Sopharma AD logo

Sopharma AD — Investor Relations & Filings

Ticker · SFA ISIN · BG11SOSOBT18 LEI · 097900BGGW0000048796 BSOBGN Manufacturing
Open in API
Filings indexed 1,481 across all filing types
Latest filing 2024-02-20 Director's Dealing
Country BG Bulgaria
Listing BSOBGN SFA

About Sopharma AD

https://www.sopharmagroup.com/

Sopharma AD is a pharmaceutical company founded in 1933 that specializes in the production, distribution, and export of a wide range of medical products. The company's portfolio includes prescription (Rx) and over-the-counter (OTC) medicines, encompassing both branded and generic drugs. A key area of focus is its traditional plant-based products. Sopharma develops treatments for various conditions, including liver disease, pain management, and smoking cessation. Operating from EU-GMP certified facilities, the company also provides contract manufacturing services and has an established presence in over 40 international markets.

Recent filings

Filing Released Lang Actions
zal01_Donev_Sopharma_EN_19022024.pdf
Director's Dealing Classification · 100% confidence The document text details a transaction involving a person discharging managerial responsibilities ('Ognian Donev') at Sopharma AD. Specifically, it reports the 'Exercising warrant rights' related to financial instruments (Warrants, ISIN №BG9200001212) and provides details on price and volume. This structure is characteristic of mandatory insider trading disclosures, which report personal share transactions by directors and executives. This aligns directly with the definition for Director's Dealing (DIRS).
2024-02-20 English
Notification for Sales revenues for January 2024
Earnings Release Classification · 95% confidence The document is very short (316 characters) and is titled 'Current report № 8/ 2024 Dated February 19, 2024'. It provides a brief, high-level summary of sales performance for January 2024 (an increase of 32% year-over-year). This format—a short, immediate notification of key operational or financial metrics—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a comprehensive report (like 10-K or IR) but rather a preliminary announcement of results, ER is the most appropriate specific category. It is not an announcement *about* a report, but the report itself in summary form. Q1 2024
2024-02-19 English
Technical error in the Notification under Art. 89t of the Law on Public Offering of Securities published on 26.01.2024
Regulatory Filings Classification · 95% confidence The document is a 'Current report №7/2024' dated January 31, 2024, correcting a previous notification regarding a capital increase ('increase of the capital... by exercising warrants'). This relates directly to changes in the company's capital structure or financing activities. While it is a correction to a previous filing, the core subject matter is capital change. The closest specific category is 'Capital/Financing Update' (CAP). It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). Given the subject matter of capital increase via warrants, CAP is the most appropriate fit, rather than the general fallback RNS.
2024-01-31 English
Individual financial report according to IFRS as of 31 December 2023
Regulatory Filings Classification · 19% confidence
2024-01-30 Polish
Notification according to Art. 89t of the LPOS concerning an increase of the capital of "SOFARMA" AD, UIC 831902088, with registered office and management address in the city of Sofia, Nadezhda dis...
Share Issue/Capital Change Classification · 99% confidence The document is a formal 'NOTIFICATION' from 'Sopharma' AD detailing the procedure for a capital increase executed through the exercise of warrants. It specifies the number of shares, the issue price, the role of the investment intermediary, the subscription term, and the legal basis (Law on the Public Offering of Securities, Commercial Code). This content directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an announcement of a report (RPA/RNS), nor is it a full annual/interim report, a management discussion, or a dividend notice.
2024-01-26 English
Sopharma AD-Sofia presented inutes of the General Meeting of Warrant Holders held on 26-01-2024 11:00 a.m
AGM Information Classification · 19% confidence
2024-01-26 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.